Sex steroids and sex hormone-binding globulin in postmenopausal women with nonalcoholic fatty liver disease

Hormones

Volumn 12, Issue 3, 2013, Pages 405-416

  Polyzos, Stergios A ^a   Kountouras, Jannis ^a   Tsatsoulis, Agathocles ^b   Zafeiriadou, Efthimia ^c   Katsiki, Evangelia ^c   Patsiaoura, Kalliopi ^c   Zavos, Christos ^a   Anastasiadou, Vasiliki V ^d   Slavakis, Aristidis ^c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c Ippokration Hospital   (Greece)

^d 'Mitera' Children's Hospital   (Greece)

Author keywords

Estradiol; Free androgen index; Insulin resistance; Metabolic syndrome; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Sex hormone binding globulin; Testosterone

Indexed keywords

ESTRADIOL; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; MOLECULAR PATHOLOGY; NONALCOHOLIC FATTY LIVER; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL;

CROSS-SECTIONAL STUDIES; ESTRADIOL; FATTY LIVER; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 84885218849     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03401306     Document Type: Article

References (35)

1. Polyzos SA, Kountouras J, Zavos C, 2009 Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 72: 299-314.
2. Vernon G, Baranova A, Younossi ZM, 2011 Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34: 274-285.
3. Polyzos SA, Kountouras J, Zavos C, Deretzi G, 2012 Nonalcoholic fatty liver disease: Multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol 46: 272-284.
4. Baranova A, Tran TP, Birerdinc A, Younossi ZM, 2011 Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 33: 801-814.
5. Vassilatou E, Lafoyianni S, Vryonidou A, et al, 2010 Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod 25: 212-220.
6. Shin JY, Kim SK, Lee MY, et al, 2011 Serum sex hormone-binding globulin levels are independently associated with nonalcoholic fatty liver disease in people with type 2 diabetes. Diabetes Res Clin Pract 94: 156-162.
7. Mojiminiyi OA, Safar FH, Al RH, Diejomaoh M, 2010 Variations in alanine aminotransferase levels within the normal range predict metabolic and androgenic phenotypes in women of reproductive age. Scand J Clin Lab Invest 70: 554-560.
8. Kauffman RP, Baker TE, Baker V, Kauffman MM, Castracane VD, 2010 Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role? Gynecol Endocrinol 26: 39-46.
9. Tian GX, Sun Y, Pang CJ, et al, 2012 Oestradiol is a protective factor for non-alcoholic fatty liver disease in healthy men. Obes Rev 13: 381-387.
10. Gutierrez-Grobe Y, Ponciano-Rodriguez G, Ramos MH, Uribe M, Mendez-Sanchez N, 2010 Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol 9: 402-409.
11. Tan S, Bechmann LP, Benson S, et al, 2010 Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. J Clin Endocrinol Metab 95: 343-348.
12. Kim S, Kwon H, Park JH, et al, 2012 A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease. BMC Gastroenterol 12: 69. doi: 10.1186/1471-230X-12-69.
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, 1985 Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
14. Vermeulen A, Verdonck L, Kaufman JM, 1999 A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84: 3666-3672.
15. Kleiner DE, Brunt EM, Van NM, et al, 2005 Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321.
16. Brand JS, van dT, I, Grobbee DE, Emmelot-Vonk MH, van der Schouw YT, 2011 Testosterone, sex hormonebinding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol 40: 189-207.
17. Selva DM, Hogeveen KN, Innis SM, Hammond GL, 2007 Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene. J Clin Invest 117: 3979-3987.
18. Yasui T, Tomita J, Miyatani Y, et al, 2007 Associations of adiponectin with sex hormone-binding globulin levels in aging male and female populations. Clin Chim Acta 386: 69-75.
19. Laaksonen DE, Niskanen L, Punnonen K, et al, 2003 Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol 149: 601-608.
20. McKenzie J, Fisher BM, Jaap AJ, Stanley A, Paterson K, Sattar N, 2006 Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebocontrolled trial. Clin Endocrinol (Oxf) 65: 40-44.
21. Kim MH, Kang KS, Lee YS, 2010 The inhibitory effect of genistein on hepatic steatosis is linked to visceral adipocyte metabolism in mice with diet-induced nonalcoholic fatty liver disease. Br J Nutr 104: 1333-1342.
22. Kamada Y, Kiso S, Yoshida Y, et al, 2011 Estrogen deficiency worsens steatohepatitis in mice fed high-fat and high-cholesterol diet. Am J Physiol Gastrointest Liver Physiol 301: G1031-G1043.
23. Fukui M, Senmaru T, Hasegawa G, et al, 2011 17beta-Estradiol attenuates saturated fatty acid diet-induced liver injury in ovariectomized mice by up-regulating hepatic senescence marker protein-30. Biochem Biophys Res Commun 415: 252-257.
24. Chow JD, Jones ME, Prelle K, Simpson ER, Boon WC, 2011 A selective estrogen receptor alpha agonist ameliorates hepatic steatosis in the male aromatase knockout mouse. J Endocrinol 210: 323-334.
25. Giannitrapani L, Soresi M, La SE, Cervello M, D'Alessandro N, Montalto G, 2006 Sex hormones and risk of liver tumor. Ann N Y Acad Sci 1089: 228-236.
26. Kountouras J, Boura P, Karolides A, Zaharioudaki E, Tsapas G, 1995 Recombinant a2 interferon (a-IFN) with chemo-hormonal therapy in patients with hepatocellular carcinoma (HCC). Hepatogastroenterology 42: 31-36.
27. Yin PH, Lee HC, Chau GY, et al, 2004 Polymorphisms of estrogen-metabolizing genes and risk of hepatocellular carcinoma in Taiwan females. Cancer Lett 212: 195-201.
28. Koehler E, Swain J, Sanderson S, Krishnan A, Watt K, Charlton M, 2012 Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients. Liver Int 32: 279-286.
29. Sumida Y, Yonei Y, Kanemasa K, et al, 2010 Lower circulating levels of dehydroepiandrosterone, independent of insulin resistance, is an important determinant of severity of non-alcoholic steatohepatitis in Japanese patients. Hepatol Res 40: 901-910.
30. Charlton M, Angulo P, Chalasani N, et al, 2008 Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology 47: 484-492.
31. Ahmed A, Rabbitt E, Brady T, et al, 2012 A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease. PLoS One 7: e29531.
32. Konopelska S, Kienitz T, Hughes B, et al, 2009 Hepatic 11beta-HSD1 mRNA expression in fatty liver and nonalcoholic steatohepatitis. Clin Endocrinol (Oxf) 70: 554-560.
33. Bedogni G, Bellentani S, Miglioli L, et al, 2006 The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6: 33.
34. Vongsuvanh R, George J, McLeod D, van der PD, 2012 Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease. J Hepatol 57: 392-398.
35. Ly LP, Sartorius G, Hull L, et al, 2010 Accuracy of calculated free testosterone formulae in men. Clin Endocrinol (Oxf) 73: 382-388.